Genetic Research And Biotech Science Con

Ultragenyx Is Uniquely Positioned In Long Term, Remains On JPMorgan’s Focus List

JPMorgan on Thursday shared updated thoughts on Ultragenyx Pharmaceutical Inc’s (NASDAQ:RARE) setrusumab program in osteogenesis imperfecta (OI).In a fourth-quarter 2024 press release, the company said patients continue dosing in the Phase 3 Orbit and Cosmic trials, which evaluate setrusumab in pediatric and young adult patients with OI.The randomized, placebo-controlled Phase 3 portion of the Orbit […]

Read More
facebook default wide s1400 c100

The Global Race for Rare Earth Minerals

The race is on for control over deposits of rare earth elements and critical minerals that are necessary in much of the technology we use today. The U.S. is lagging behind it’s main rival in this global competition, China. We hear about why these resources are so sought after and the stakes in the race […]

Read More